Altimmune, Inc. (NASDAQ:ALT) Sees Significant Decrease in Short Interest

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) was the recipient of a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 23,320,000 shares, a drop of 5.2% from the January 15th total of 24,590,000 shares. Based on an average trading volume of 3,190,000 shares, the short-interest ratio is currently 7.3 days.

Altimmune Stock Down 3.0 %

Shares of ALT stock traded down $0.20 during trading hours on Friday, reaching $6.43. The company's stock had a trading volume of 1,637,662 shares, compared to its average volume of 2,156,376. The firm's 50 day simple moving average is $7.11 and its 200-day simple moving average is $7.18. The company has a market capitalization of $457.30 million, a price-to-earnings ratio of -4.15 and a beta of 0.19. Altimmune has a fifty-two week low of $5.28 and a fifty-two week high of $14.84.

Analyst Ratings Changes

ALT has been the topic of a number of recent research reports. HC Wainwright restated a "buy" rating and set a $12.00 price objective on shares of Altimmune in a research note on Wednesday, February 5th. UBS Group assumed coverage on Altimmune in a research note on Tuesday, November 12th. They set a "buy" rating and a $26.00 price objective on the stock. Finally, Stifel Nicolaus assumed coverage on Altimmune in a report on Wednesday, January 8th. They issued a "buy" rating and a $18.00 target price on the stock. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Altimmune currently has an average rating of "Buy" and an average price target of $20.83.

Institutional Investors Weigh In On Altimmune

Hedge funds have recently modified their holdings of the company. Bellevue Group AG boosted its holdings in shares of Altimmune by 43.9% during the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company's stock valued at $5,303,000 after acquiring an additional 263,660 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Altimmune during the 3rd quarter valued at $674,000. Barclays PLC boosted its holdings in shares of Altimmune by 93.0% during the 3rd quarter. Barclays PLC now owns 155,741 shares of the company's stock valued at $956,000 after acquiring an additional 75,064 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Altimmune by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company's stock valued at $1,299,000 after acquiring an additional 4,772 shares in the last quarter. Finally, Stifel Financial Corp boosted its holdings in shares of Altimmune by 77.4% during the 3rd quarter. Stifel Financial Corp now owns 17,752 shares of the company's stock valued at $109,000 after acquiring an additional 7,746 shares in the last quarter. Institutional investors and hedge funds own 78.05% of the company's stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.